## Carsten Skarke

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/69610/publications.pdf

Version: 2024-02-01

60 2,537 25 49 papers citations h-index g-index

63 63 63 2656 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Genetic Predictors of the Clinical Response to Opioid Analgesics. Clinical Pharmacokinetics, 2004, 43, 983-1013.	1.6	230
2	The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics and Genomics, 2002, 12, 3-9.	5.7	201
3	Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clinical Pharmacology and Therapeutics, 2003, 73, 107-121.	2.3	187
4	Olfactory Function in Mild Cognitive Impairment and Alzheimer's Disease: An Investigation Using Psychophysical and Electrophysiological Techniques. American Journal of Psychiatry, 2003, 160, 1995-2002.	4.0	152
5	Does the A118G Polymorphism at the μ-opioid Receptor Gene Protect against Morphine-6-Glucuronide Toxicity?. Anesthesiology, 2002, 97, 814-819.	1.3	149
6	The Transfer Half-life of Morphine-6-glucuronide from Plasma to Effect Site Assessed by Pupil Size Measurement in Healthy Volunteers. Anesthesiology, 2001, 95, 1329-1338.	1.3	120
7	Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics and Genomics, 2003, 13, 651-660.	5 <b>.</b> 7	106
8	Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury. Molecular Metabolism, 2017, 6, 1395-1406.	3.0	103
9	Enhanced absorption of boswellic acids by a lecithin delivery form (Phytosome®) of Boswellia extract. F¬toterapìâ, 2013, 84, 89-98.	1.1	101
10	Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clinical Pharmacology and Therapeutics, 2006, 79, 72-89.	2.3	91
11	Bioactive products formed in humans from fish oils. Journal of Lipid Research, 2015, 56, 1808-1820.	2.0	83
12	Identification of Human Cathepsin G As a Functional Target of Boswellic Acids from the Anti-Inflammatory Remedy Frankincense. Journal of Immunology, 2009, 183, 3433-3442.	0.4	72
13	A Pilot Characterization of the Human Chronobiome. Scientific Reports, 2017, 7, 17141.	1.6	70
14	Evidence for morphine-independent central nervous opioid effects after administration of codeine: Contribution of other codeine metabolites. Clinical Pharmacology and Therapeutics, 2006, 79, 35-48.	2.3	68
15	Pharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers*. Clinical Pharmacology and Therapeutics, 2002, 72, 151-162.	2.3	65
16	Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clinical Pharmacology and Therapeutics, 2003, 74, 303-311.	2.3	59
17	Increased Bioavailability of 11â€Ketoâ€Î²â€Boswellic Acid Following Single Oral Dose Frankincense Extract Administration After a Standardized Meal in Healthy Male Volunteers: Modeling and Simulation Considerations for Evaluating Drug Exposures. Journal of Clinical Pharmacology, 2012, 52, 1592-1600.	1.0	53
18	Drug Interactions with Patient-Controlled Analgesia. Clinical Pharmacokinetics, 2002, 41, 31-57.	1.6	51

#	Article	IF	CITATIONS
19	On the interference of boswellic acids with 5-lipoxygenase: Mechanistic studies in vitro and pharmacological relevance. European Journal of Pharmacology, 2009, 606, 246-254.	1.7	51
20	Effects of selective COXâ€2 inhibition on prostanoids and platelet physiology in young healthy volunteers. Journal of Thrombosis and Haemostasis, 2007, 5, 2376-2385.	1.9	47
21	The 5-hydroxytryptamine 4 receptor agonist mosapride does not antagonize morphine-induced respiratory depression. Clinical Pharmacology and Therapeutics, 2005, 78, 278-287.	2.3	45
22	CMPF, a Metabolite Formed Upon Prescription Omega-3-Acid Ethyl Ester Supplementation, Prevents and Reverses Steatosis. EBioMedicine, 2018, 27, 200-213.	2.7	35
23	Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing. European Journal of Clinical Pharmacology, 2005, 61, 887-892.	0.8	33
24	The cyclooxygenase 2 genetic variant â^765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. Clinical Pharmacology and Therapeutics, 2006, 80, 621-632.	2.3	30
25	Comprehensive Mu-Opioid-Receptor Genotyping by Pyrosequencing. Clinical Chemistry, 2004, 50, 640-644.	1.5	28
26	A rapid screening method for a single nucleotide polymorphism (SNP) in the human MOR gene. British Journal of Clinical Pharmacology, 2001, 52, 711-714.	1.1	24
27	Probenecid Interacts with the Pharmacokinetics of Morphine-6-glucuronide in Humans. Anesthesiology, 2004, 101, 1394-1399.	1.3	22
28	Guidelines for the design and conduct of human clinical trials on ingestion-time differences $\hat{a} \in \text{``}$ chronopharmacology and chronotherapy $\hat{a} \in \text{''}$ of hypertension medications. Chronobiology International, 2021, 38, 1-26.	0.9	22
29	Effects of the opioid remifentanil on olfactory function in healthy volunteers. Life Sciences, 2001, 69, 2279-2285.	2.0	21
30	Is morphine-3-glucuronide of therapeutic relevance?. Pain, 2005, 116, 177-180.	2.0	21
31	Training Translators for Smart Drug Discovery. Science Translational Medicine, 2010, 2, 26cm12.	5.8	20
32	Pharmacokinetics of morphine are not altered in subjects with Gilbert's syndrome. British Journal of Clinical Pharmacology, 2003, 56, 228-231.	1.1	19
33	Simultaneous screening for three mutations in the ABCB1 gene. Genomics, 2003, 82, 503-510.	1.3	19
34	Pyrosequencingâ,,¢ of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance. Pharmacogenomics, 2007, 8, 1643-1660.	0.6	19
35	Nitecap: An Exploratory Circadian Analysis Web Application. Journal of Biological Rhythms, 2022, 37, 43-52.	1.4	18
36	Comparative Impact on Prostanoid Biosynthesis of Celecoxib and the Novel Nonsteroidal Anti-Inflammatory Drug CG100649. Clinical Pharmacology and Therapeutics, 2012, 91, 986-993.	2.3	16

#	Article	IF	Citations
37	The influence of inhibition of probenecid sensitive transporters on the central nervous system (CNS) uptake and the antinociceptive activity of morphine-6-glucuronide in rats. Neuroscience Letters, 2002, 329, 145-148.	1.0	13
38	Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencingâ,,¢. Pharmacogenomics, 2006, 7, 167-176.	0.6	10
39	Myrtucommulone from Myrtus communis: Metabolism, Permeability, and Systemic Exposure in Rats. Planta Medica, 2012, 78, 1932-1938.	0.7	10
40	GCG100649, A Novel Cyclooxygenaseâ€2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydraseâ€I/II: Preliminary Dose–Exposure Relationships to Define Clinical Development Strategies. Clinical Pharmacology in Drug Development, 2013, 2, 379-386.	0.8	10
41	No increase in inflammation in late-life major depression screened to exclude physical illness. Translational Psychiatry, 2022, 12, 118.	2.4	9
42	Considerations for the Safe Operation of Schools During the Coronavirus Pandemic. Frontiers in Public Health, 2021, 9, 751451.	1.3	9
43	Morphine metabolites: Clinical implications. Seminars in Anesthesia, 2002, 21, 258-264.	0.3	5
44	Time-specific associations of wearable sensor-based cardiovascular and behavioral readouts with disease phenotypes in the outpatient setting of the Chronic Renal Insufficiency Cohort. Digital Health, 2022, 8, 205520762211079.	0.9	4
45	Non-invasive combined surrogates of remifentanil blood concentrations with relevance to analgesia. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 865-873.	1.4	3
46	Selective COX-2 Inhibitors Suppress Prostacyclin. Clinical Therapeutics, 2014, 36, 2120-2121.	1.1	1
47	Diet-Epigenome Axis. Circulation Genomic and Precision Medicine, 2020, 13, e003129.	1.6	1
48	Obesity: It's (Kind of) Genetic. Science Translational Medicine, 2012, 4, .	5.8	1
49	Dissecting the Mystery Around Multiple Sclerosis. Science Translational Medicine, 2012, 4, .	<b>5.</b> 8	1
50	A Painful Question of Metabolism. Science Translational Medicine, 2012, 4, .	5.8	0
51	You May Feel Some Discomfort—or Not!. Science Translational Medicine, 2012, 4, .	5.8	0
52	May the Resolvins Be with You…. Science Translational Medicine, 2012, 4, .	5.8	0
53	Getting to the Root of SLOS. Science Translational Medicine, 2012, 4, .	5.8	0
54	Selected Microbes Light the Flame. Science Translational Medicine, 2012, 4, .	5.8	0

#	Article	IF	Citations
55	How Much Alcohol Is Too Much?. Science Translational Medicine, 2012, 4, .	5.8	O
56	A Mechanism of Interest as We Grow Older. Science Translational Medicine, 2012, 4, .	5 <b>.</b> 8	0
57	"Honey, Have You Taken Your Polyphenols Today?". Science Translational Medicine, 2012, 4, .	5 <b>.</b> 8	O
58	Catching a Glimpse of Gut Bacteria–Drug Interactions. Science Translational Medicine, 2013, 5, .	5.8	0
59	Bioinspired Glue for Healing Atherosclerotic Plaques. Science Translational Medicine, 2013, 5, .	5.8	O
60	Insights into Aging Vessels. Science Translational Medicine, 2013, 5, .	5.8	0